A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease

Trial Profile

A Phase 2, Randomized, Double-dummy, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-923 (Dextromethorphan/Quinidine) for the Treatment of Symptoms of Agitation in Patients With Alzheimer's Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2015

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 22 Sep 2015 Results published in the JAMA: the Journal of the American Medical Association.
    • 22 Sep 2015 Results presented in the Journal of the American Medical Association (JAMA), as per Avanir Pharmaceuticals media release.
    • 22 Sep 2015 Results published in Avanir Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top